UroGen Pharma Ltd.·4

Nov 18, 4:04 PM ET

Mullennix Stephen 4

4 · UroGen Pharma Ltd. · Filed Nov 18, 2019

Insider Transaction Report

Form 4
Period: 2019-11-14
Mullennix Stephen
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2019-11-14+1,7598,291 total
  • Exercise/Conversion

    Restricted Stock Units

    2019-11-141,7598,796 total
    Ordinary Shares (1,759 underlying)
  • Sale

    Ordinary Shares

    2019-11-14$26.00/sh608$15,8067,683 total
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
  • [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  • [F3]The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION